Synergistic Meropenem/Vaborbactam Plus Fosfomycin Treatment of KPC Producing K. pneumoniae Septic Thrombosis Unresponsive to Ceftazidime/Avibactam: From the Bench to the Bedside
Authors:
- Alessandra OlivaAOAlessandra Oliva
- Ambrogio CurtoloACAmbrogio Curtolo
- Lorenzo VolpicelliLVLorenzo Volpicelli
- Francesco Cogliati DezzaFDFrancesco Cogliati Dezza
- Massimiliano De AngelisMAMassimiliano De Angelis
- Sara CairoliSCSara Cairoli
- Donatella Dell’utriDDDonatella Dell’utri
- Bianca Maria GoffredoBGBianca Maria Goffredo
- Giammarco RaponiGRGiammarco Raponi
- Mario VendittiMVMario Venditti
Open Access
- 27 June 2021
- journal article
- case report
- Published by MDPI AG in Antibiotics
- Vol. 10 (7) , 781
Abstract
Gram-negative bacilli septic thrombosis (GNB-ST) represents a subtle and often misleading condition, potentially fatal if not recognized early and requiring prolonged antimicrobial therapy and anticoagulation. Herein, reported for the first time, is a very challenging case of Klebsiella producing carbapenemase (KPC)-producing K. pneumoniae (KPC-Kp) ST unresponsive to ceftazidime/avibactam (CZA) relapsed first with meropenem/vaborbactam (MVB) monotherapy and subsequently cured with MVB plus fosfomycin (FOS) combination. The present case highlights the possibility of CZA underexposure on the infected thrombus and the risk of in vivo emergence of CZA resistance in the setting of persistent bacteremia and sub-optimal anticoagulation. Pharmacokinetic analyses showed that both MVB and FOS were in the therapeutic range. In vitro studies demonstrated a high level of MVB + FOS synergism that possibly allowed definitive resolution of the endovascular infection.Keywords
This publication has 22 references indexed in Scilit:
- Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam ResistanceAntimicrobial Agents and Chemotherapy, 2018
- Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae InfectionsAntimicrobial Agents and Chemotherapy, 2018
- Imipenem–Relebactam and Meropenem–Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor CombinationsDrugs, 2017
- Follow-up Blood Cultures: A 2.0 Diagnostic Tool in Patients With Gram-Negative Bacteremia and Septic ThrombophlebitisClinical Infectious Diseases, 2017
- Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2016
- Candidal thrombophlebitis of central veins: case report and reviewMedical Mycology, 2012
- Septic ThrombophlebitisAmerican Journal of Cardiovascular Drugs, 2006
- Pharmacodynamics of antibiotics in fibrin clotsJournal of Antimicrobial Chemotherapy, 1993
- Candida Septic Thrombosis of the Great Central Veins Associated with Central CathetersAnnals of Surgery, 1985
- Suppurative ThrombophlebitisNew England Journal of Medicine, 1970